AlgiPharma attended the LNP Formulation & Process Development conference in Boston, MA (17-19th April). Chief Scientific Officer Dr. Philip Rye presented AlgiPharma’s novel alginate oligosaccharide technology for overcoming inhalation barriers for LNP delivered therapeutics. His presentation highlighted the benefits and challenges associated with the inhalation delivery route, and how AlgiPharma’s technology can mediate the effective translocation of LNP therapeutics across the mucosal barrier.
AlgiPharma’s alginate oligosaccharide technology combined with existing LNP formulations represent a novel way to safely circumvent mucosal barrier challenges and significantly increase efficiency of inhaled LNP therapeutics.
About AlgiPharma AS:
AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway. AlgiPharma has completed 5 clinical trials with two formulations of its lead drug candidate, OligoG, to treat respiratory symptoms of cystic fibrosis. AlgiPharma is developing its proprietary alginate technology for:
- Delivery platforms for nanoparticles, small and large molecule based drugs.
- Drug conjugates, adding functionality and reducing toxicity of parent compound.
- API in disease areas such as cystic fibrosis, COPD, and infectious diseases.
AlgiPharma has pharmaceutical scale production capabilities for its technology protected by a broad family of patents.
AlgiPharma owns or licenses all relevant patents upon which the technology platform and products are developed. The company is supported by national and international research programs, and collaborates with a network of key opinion leaders, highly recognized academic institutions, research and patient organizations in Europe and USA.
AlgiPharma has received more than USD 46 million in research and development grants from EU’s 7th framework program, Horizon 2020, and Eurostars programs, the Norwegian Research Council, Innovate UK, Innovation Norway, US Army through Congressional Earmark funding, the Australian R&D Tax Incentive, and the Cystic Fibrosis Foundation (CFF).
AlgiPharma is a privately owned company registered and domiciled in Norway.
For additional information contact:
Yngvar P. Berg, CEO: firstname.lastname@example.org
Arne Dessen, COO and Chairman of the Board: email@example.com